211 related articles for article (PubMed ID: 11383754)
1. The cost of treatment of Alzheimer's disease in The Netherlands: a regression-based simulation model.
McDonnell J; Redekop WK; van der Roer N; Goes E; Ruitenberg A; Busschbach JJ; Breteler MM; Rutten FF
Pharmacoeconomics; 2001; 19(4):379-90. PubMed ID: 11383754
[TBL] [Abstract][Full Text] [Related]
2. The Potential Impact of Alzheimer's Disease Early Treatment on Societal Costs of Care in Czechia: A Simulation Approach.
Broulikova HM; Sladek V; Arltova M; Cerny J
J Ment Health Policy Econ; 2018 Dec; 21(4):147-161. PubMed ID: 30676992
[TBL] [Abstract][Full Text] [Related]
3. Potential cost savings to be made by slowing cognitive decline in mild Alzheimer's disease dementia using a model derived from the UK GERAS observational study.
Lenox-Smith A; Reed C; Lebrec J; Belger M; Jones RW
BMC Geriatr; 2018 Feb; 18(1):57. PubMed ID: 29471784
[TBL] [Abstract][Full Text] [Related]
4. Rivastigmine. A pharmacoeconomic review of its use in Alzheimer's disease.
Lamb HM; Goa KL
Pharmacoeconomics; 2001; 19(3):303-18. PubMed ID: 11303418
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of galantamine, a cholinesterase inhibitor, in the treatment of patients with mild to moderate Alzheimer's disease in the Netherlands.
Caro JJ; Salas M; Ward A; Getsios D; Mehnert A;
Dement Geriatr Cogn Disord; 2002; 14(2):84-9. PubMed ID: 12145455
[TBL] [Abstract][Full Text] [Related]
6. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Jones RW; McCrone P; Guilhaume C
Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
[TBL] [Abstract][Full Text] [Related]
7. Economic considerations in Alzheimer's disease.
Meek PD; McKeithan K; Schumock GT
Pharmacotherapy; 1998; 18(2 Pt 2):68-73; discussion 79-82. PubMed ID: 9543467
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
Garfield FB; Getsios D; Caro JJ; Wimo A; Winblad B
Pharmacoeconomics; 2002; 20(9):629-37. PubMed ID: 12141890
[TBL] [Abstract][Full Text] [Related]
9. Relation between severity of Alzheimer's disease and costs of caring.
Hux MJ; O'Brien BJ; Iskedjian M; Goeree R; Gagnon M; Gauthier S
CMAJ; 1998 Sep; 159(5):457-65. PubMed ID: 9757169
[TBL] [Abstract][Full Text] [Related]
10. Alzheimer's dementia: budget impact and cost-utility analysis of a combination treatment of a cholinesterase inhibitor and memantine in Switzerland.
Pfeil AM; Kressig RW; Szucs TD
Swiss Med Wkly; 2012; 142():w13676. PubMed ID: 23180021
[TBL] [Abstract][Full Text] [Related]
11. Modelling the cost effectiveness of cholinesterase inhibitors in the management of mild to moderately severe Alzheimer's disease.
Green C; Picot J; Loveman E; Takeda A; Kirby J; Clegg A
Pharmacoeconomics; 2005; 23(12):1271-82. PubMed ID: 16336020
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Florbetapir-PET in Alzheimer's Disease: A Spanish Societal Perspective.
Hornberger J; Michalopoulos S; Dai M; Andrade P; Dilla T; Happich M
J Ment Health Policy Econ; 2015 Jun; 18(2):63-73. PubMed ID: 26231002
[TBL] [Abstract][Full Text] [Related]
13. Estimation of the family cost of private nursing home care versus home care for patients with dementia in Taiwan.
Chiu L; Shyu WC
Chang Gung Med J; 2001 Oct; 24(10):608-14. PubMed ID: 11771182
[TBL] [Abstract][Full Text] [Related]
14. [Costs of health care resources of ambulatory-care patients diagnosed with Alzheimer's disease in Spain].
Boada M; Peña-Casanova J; Bermejo F; Guillén F; Hart WM; Espinosa C; Rovira J
Med Clin (Barc); 1999 Nov; 113(18):690-5. PubMed ID: 10650570
[TBL] [Abstract][Full Text] [Related]
15. Potential savings in the cost of caring for Alzheimer's disease. Treatment with rivastigmine.
Hauber AB; Gnanasakthy A; Snyder EH; Bala MV; Richter A; Mauskopf JA
Pharmacoeconomics; 2000 Apr; 17(4):351-60. PubMed ID: 10947490
[TBL] [Abstract][Full Text] [Related]
16. The economic impact of the tacrine in the treatment of Alzheimer's disease.
Henke CJ; Burchmore MJ
Clin Ther; 1997; 19(2):330-45. PubMed ID: 9152571
[TBL] [Abstract][Full Text] [Related]
17. Economic impact of introducing propentofylline for the treatment of dementia in Sweden.
Wimo A; Witthaus E; Rother M; Winblad B
Clin Ther; 1998; 20(3):552-66; discussion 550-1. PubMed ID: 9663370
[TBL] [Abstract][Full Text] [Related]
18. The economic costs of Alzheimer's disease.
Hay JW; Ernst RL
Am J Public Health; 1987 Sep; 77(9):1169-75. PubMed ID: 3113273
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
20. Prospective one-year cost-of-illness study in a cohort of patients with dementia of Alzheimer's disease type in Spain: the ECO study.
Coduras A; Rabasa I; Frank A; Bermejo-Pareja F; López-Pousa S; López-Arrieta JM; Del Llano J; León T; Rejas J
J Alzheimers Dis; 2010; 19(2):601-15. PubMed ID: 20110605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
